Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods.
about
Deep Response in Multiple Myeloma: A Critical ReviewResistant mutations in CML and Ph(+)ALL - role of ponatinib.Current developments in molecular monitoring in chronic myeloid leukemiaChronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responsesSignificance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?Interpreting molecular monitoring results and international standardization in chronic myeloid leukemia.Targeted treatment of chronic myeloid leukemia: role of imatinib.Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapyEfficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy.Chronic myelogenous leukemia: treatment and monitoring.Interpretation of cytogenetic and molecular results in patients treated for CML.Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid LeukemiaPersonalizing health care: feasibility and future implications.Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.How I treat childhood CML.MiR-362-5p promotes the malignancy of chronic myelocytic leukaemia via down-regulation of GADD45α.Philadelphia-negative chronic myeloproliferative neoplasmsABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.How I monitor residual disease in chronic myeloid leukemia.Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.Current status of therapy for chronic myeloid leukemia: a review of drug development.Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.A successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib.Kinase drug discovery approaches in chronic myeloproliferative disorders.Molecular diagnosis of myeloproliferative neoplasms.How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.State-of-the-art in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors: evolutionary trends in diagnosis, monitoring and treatment.The role of molecular genetic analysis within the diagnostic haemato-oncology laboratory.Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia.BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management.A Preliminary Study of the Suitability of Archival Bone Marrow and Peripheral Blood Smears for Diagnosis of CML Using FISHChronic myeloid leukemia: past, present, future.FuseFISH: robust detection of transcribed gene fusions in single cells.Chronic myeloid leukemia in case of Klinefelter syndrome.Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.Molecular characterization of canine BCR-ABL-positive chronic myelomonocytic leukemia before and after chemotherapy.
P2860
Q26771228-B02EC854-679D-4B0A-AA64-E9200B8D3510Q27853085-F6E943C1-532E-4D89-97A7-C3E77DEFF02CQ28066148-7BFE6DE0-EBD9-4D6C-B39F-86741F803A78Q28475717-7FE6E613-7EA0-4D41-B8CD-EE97A624A5C2Q33561232-4B0C43D0-A880-481F-8EB4-3BAEACFD95C1Q33857947-790C8958-E0BA-493F-AC9A-144A84F6036CQ33885583-DAFBB226-4691-4F40-B974-B33C93A43CDBQ33915973-5ACBAA26-4E71-445C-B5C9-DBE2A8BB3E7AQ34302673-E398935A-8622-4847-B235-B12AAE62E297Q34480473-3C5146DF-05CD-4B4E-A254-2D066D05FA55Q34617628-308970F3-BB38-4A4C-85F7-F2654ED6E68BQ34765448-92F94A84-90F2-4F96-9276-265AAAF41AC4Q34781322-EAFB59EF-4589-474D-94AF-6ACDD1E45AF9Q34938911-427BBB3E-371B-4D34-8842-1E942FD07EE8Q35694453-674EAA88-E597-4485-9F24-867C5E04D65CQ35794105-C5EC4796-E4DA-481F-B69D-624F149AF011Q35802202-DEFFC605-A67A-48B0-90C8-7797A94D19DBQ36259116-B27CF7EC-0A5E-4F5A-B441-A41E01439E87Q36283143-0003A7AC-A6B5-42F1-9E42-01CBE1310492Q36353183-73C8449C-38C9-4E89-8468-B243896A408CQ36846361-62F744D0-4C98-48AD-8828-C46C099B75BAQ37148391-EB253208-B368-498F-A49E-9C8BFDD62644Q37163550-F0C9A6B4-5B35-442C-B24C-7B814C537966Q37179388-243762D6-16AF-435C-8B6B-0197B801CFE4Q37271941-FF581729-7D11-4E9C-87F4-3CF44DD3C697Q37362975-9FE419DC-6771-4427-ACB2-670D4C0C3A73Q37472874-17F85B3C-10F5-4F53-8E3D-E36AD85429C1Q37542270-8D351382-0E0F-4D13-B676-D0084A05FD05Q37545067-51D6F7CC-0765-4044-92EF-ED6CF5FA7F2FQ37657478-ED707F08-F271-4328-864B-B535ABCC49EBQ37924989-BB406F6F-7B47-40BB-99B2-CD0AD8F183FDQ38050752-A78024AD-16B3-468A-A2B1-83EA99F5173EQ38142258-F6C61F01-74A3-4B55-B3F0-2821E8729658Q38204330-F1F50E86-2AD6-4907-8422-69BA15467C0BQ38389692-CA6D20D7-EA51-4031-A707-B53E7F08844FQ38694690-D6B96551-9B79-4DA9-9FE0-E66A63E59CDEQ39038984-DC3EBEDB-014A-47B8-A996-783C740195E8Q40953266-4BDB2EEC-2F5C-4E98-9EB3-5468ABAFA6C3Q40957470-99A66E23-CAA9-4463-8BB6-D9A1CD2FB882Q41461273-AB782CD4-3D8A-4F65-AEC2-E462ED8717D0
P2860
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Monitoring the response and co ...... etation of monitoring methods.
@en
Monitoring the response and co ...... etation of monitoring methods.
@nl
type
label
Monitoring the response and co ...... etation of monitoring methods.
@en
Monitoring the response and co ...... etation of monitoring methods.
@nl
prefLabel
Monitoring the response and co ...... etation of monitoring methods.
@en
Monitoring the response and co ...... etation of monitoring methods.
@nl
P1433
P1476
Monitoring the response and co ...... etation of monitoring methods.
@en
P2093
Charles Schiffer
P304
P356
10.1182/BLOOD-2007-09-110189
P407
P577
2007-11-30T00:00:00Z